BEAM

Beam Therapeutics Inc. NASDAQ Listed Feb 6, 2020

Healthcare ·Biotechnology ·US · beamtx.com

$32.34

After hrs $31.62 -2.21%

Mkt Cap $3.3B

52w Low $15.35 80.6% of range 52w High $36.44

50d MA $27.30 200d MA $25.12

P/E (TTM) -37.9x

EV/EBITDA -91.6x

P/B 2.5x

Debt/Equity 0.2x

ROE -6.5%

P/FCF -7.6x

RSI (14) —

ATR (14) —

Beta 2.19

50d MA $27.30

200d MA $25.12

Avg Volume 2.0M

About

Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refract…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 24, 2026	BMO	-1.13	-0.10	+91.2%	32.29	+2.2%	-8.3%	-8.3%	-10.4%	-11.9%	-11.1%	—
Nov 4, 2025	BMO	-0.98	-1.10	-12.2%	22.74	+1.0%	+1.5%	+1.5%	+1.8%	-2.3%	-4.8%	—
Aug 5, 2025	BMO	-1.04	-1.00	+3.8%	18.70	-2.1%	-2.1%	-2.1%	-4.5%	-5.8%	-8.2%	—
May 6, 2025	BMO	-1.11	-1.24	-11.7%	15.99	+1.3%	+1.5%	+1.5%	+7.9%	+8.9%	+14.1%	—
Feb 25, 2025	BMO	-1.25	-1.09	+12.8%	29.84	-0.0%	-6.5%	-6.5%	-9.1%	-11.7%	-15.9%	—
Nov 5, 2024	BMO	-1.13	-1.17	-3.5%	23.93	+8.7%	+11.2%	+11.2%	+9.1%	+13.1%	+26.8%	—
Aug 6, 2024	BMO	-1.13	-1.11	+1.8%	25.52	-0.0%	-4.2%	-4.2%	-2.4%	-4.2%	-6.0%	—
May 7, 2024	BMO	-1.45	-1.21	+16.6%	22.53	-3.6%	-1.3%	-1.3%	+0.0%	-5.6%	+6.6%	—
Feb 27, 2024	BMO	-1.01	1.73	+271.3%	45.07	-0.5%	-3.2%	-3.2%	-12.4%	-11.6%	-15.2%	—
Nov 8, 2023	BMO	-1.37	-1.22	+10.9%	22.90	+1.2%	-3.0%	-3.0%	-3.2%	-4.2%	+7.2%	—
Aug 8, 2023	BMO	-1.38	-1.08	+21.7%	26.25	+0.6%	-0.5%	-0.5%	-3.2%	-2.7%	-3.9%	—
May 10, 2023	BMO	-1.36	-1.33	+2.2%	35.85	-0.8%	-1.9%	-1.9%	-7.0%	+0.4%	-5.6%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 26	Citigroup	Maintains	Buy → Buy	—	$23.12	$23.15	+0.1%	+2.2%	-4.0%	-5.3%	+3.1%	+4.8%
Feb 25	Wedbush	Maintains	Outperform → Outperform	—	$32.29	$33.00	+2.2%	-8.3%	-10.4%	-11.9%	-11.1%	-15.7%
Feb 25	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$32.29	$33.00	+2.2%	-8.3%	-10.4%	-11.9%	-11.1%	-15.7%
Jan 21	Bernstein	Maintains	Outperform → Outperform	—	$30.97	$30.84	-0.4%	+0.5%	+10.6%	+1.9%	-0.1%	-0.9%
Oct 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.87	$28.48	+2.2%	-5.6%	-8.9%	-8.8%	-2.4%	-7.5%
Oct 9	JP Morgan	Maintains	Overweight → Overweight	—	$27.00	$27.15	+0.6%	+3.2%	-2.5%	-6.0%	-5.9%	+0.7%
Sep 15	HC Wainwright & Co.	Maintains	Buy → Buy	—	$20.60	$20.88	+1.4%	+3.3%	+11.2%	+9.0%	+21.8%	+18.1%
Aug 6	Barclays	Maintains	Equal Weight → Equal Weight	—	$18.70	$18.31	-2.1%	-2.1%	-4.5%	-5.8%	-8.2%	-9.8%
May 7	Wells Fargo	Maintains	Overweight → Overweight	—	$15.99	$16.20	+1.3%	+1.5%	+7.9%	+8.9%	+14.1%	+12.9%
May 7	Guggenheim	Maintains	Buy → Buy	—	$15.99	$16.20	+1.3%	+1.5%	+7.9%	+8.9%	+14.1%	+12.9%
May 7	Barclays	Maintains	Equal Weight → Equal Weight	—	$15.99	$16.20	+1.3%	+1.5%	+7.9%	+8.9%	+14.1%	+12.9%
Apr 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$15.27	$14.51	-5.0%	+0.2%	-4.8%	+7.2%	-4.2%	+1.3%
Mar 28	BofA Securities	Upgrade	Neutral → Buy	—	$22.19	$22.54	+1.6%	+0.1%	-12.0%	-20.5%	-16.7%	-25.8%
Mar 12	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$26.42	$26.91	+1.9%	+3.8%	-5.1%	-8.3%	-7.2%	-14.5%
Mar 10	HC Wainwright & Co.	Maintains	Buy → Buy	—	$28.48	$27.84	-2.2%	-9.8%	-7.2%	-3.7%	-12.0%	-14.9%
Mar 10	Jones Trading	Upgrade	Hold → Buy	—	$28.48	$27.84	-2.2%	-9.8%	-7.2%	-3.7%	-12.0%	-14.9%
Mar 10	Scotiabank	Upgrade	Sector Perform → Sector Outperform	—	$28.48	$27.84	-2.2%	-9.8%	-7.2%	-3.7%	-12.0%	-14.9%
Mar 3	Scotiabank	Maintains	Sector Perform → Sector Perform	—	$26.34	$26.54	+0.8%	-4.7%	+0.4%	-0.9%	+3.5%	+8.1%
Feb 28	HC Wainwright & Co.	Maintains	Buy → Buy	—	$27.11	$26.77	-1.3%	-2.8%	-7.4%	-2.5%	-3.7%	+0.5%
Feb 27	Guggenheim	Maintains	Buy → Buy	—	$27.89	$28.22	+1.2%	-2.8%	-5.6%	-10.0%	-5.2%	-6.4%
Feb 26	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$29.84	$29.83	-0.0%	-6.5%	-9.1%	-11.7%	-15.9%	-11.4%
Feb 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.92	$25.02	-3.5%	-1.3%	-0.7%	+7.3%	+6.7%	+5.7%
Jan 29	Cantor Fitzgerald	Upgrade	Neutral → Overweight	—	$25.26	$26.10	+3.3%	+2.6%	+8.0%	+2.6%	+1.3%	+1.9%
Dec 9	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.71	$27.76	+3.9%	+3.0%	+13.1%	+8.2%	+5.1%	+4.6%
Nov 7	HC Wainwright & Co.	Maintains	Buy → Buy	—	$26.62	$26.56	-0.2%	-2.0%	+1.7%	+14.0%	+5.0%	+3.3%
Nov 6	Leerink Partners	Upgrade	Market Perform → Outperform	—	$23.93	$26.00	+8.7%	+11.2%	+9.1%	+13.1%	+26.8%	+16.8%
Nov 6	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$23.93	$26.00	+8.7%	+11.2%	+9.1%	+13.1%	+26.8%	+16.8%
Sep 19	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$25.51	$26.66	+4.5%	+2.1%	+0.5%	-3.1%	-2.9%	-4.0%
Sep 11	Stifel	Maintains	Buy → Buy	—	$23.65	$23.65	+0.0%	+2.0%	+3.2%	+11.2%	+8.3%	+8.2%
Aug 22	HC Wainwright & Co.	Maintains	Buy → Buy	—	$25.49	$25.65	+0.6%	-3.8%	+5.2%	+6.4%	+3.1%	+2.2%
Aug 7	Barclays	Maintains	Equal Weight → Equal Weight	—	$25.52	$25.51	-0.0%	-4.2%	-2.4%	-4.2%	-6.0%	-4.6%
Aug 7	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$25.52	$25.51	-0.0%	-4.2%	-2.4%	-4.2%	-6.0%	-4.6%
Aug 7	JP Morgan	Maintains	Overweight → Overweight	—	$25.52	$25.51	-0.0%	-4.2%	-2.4%	-4.2%	-6.0%	-4.6%
May 8	Barclays	Maintains	Equal Weight → Equal Weight	—	$22.53	$21.71	-3.6%	-1.3%	+0.0%	-5.6%	+6.6%	+5.7%
Apr 23	Wedbush	Maintains	Outperform → Outperform	—	$24.10	$24.04	-0.2%	-2.6%	-5.6%	-10.4%	-11.3%	-8.5%
Mar 27	BMO Capital	Maintains	Outperform → Outperform	—	$33.22	$33.56	+1.0%	+2.2%	-0.5%	-1.7%	-8.0%	-10.7%
Feb 28	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$45.07	$44.85	-0.5%	-3.2%	-12.4%	-11.6%	-15.2%	-14.6%
Feb 28	Barclays	Maintains	Equal Weight → Equal Weight	—	$45.07	$44.85	-0.5%	-3.2%	-12.4%	-11.6%	-15.2%	-14.6%
Jan 29	JP Morgan	Upgrade	Neutral → Overweight	—	$24.29	$26.05	+7.2%	+16.5%	+6.4%	+0.5%	+8.8%	+6.7%
Dec 15	BofA Securities	Downgrade	Buy → Neutral	—	$29.79	$29.39	-1.3%	-4.6%	-7.9%	-0.9%	-7.3%	-5.8%
Dec 8	Jefferies	Downgrade	Buy → Hold	—	$28.75	$27.49	-4.4%	-8.2%	-7.3%	-9.4%	-1.6%	+3.6%
Oct 17	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$22.31	$22.02	-1.3%	-0.2%	-6.8%	-17.7%	-20.7%	-14.4%
Sep 13	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$26.18	$26.00	-0.7%	-4.4%	-4.0%	-4.3%	-7.1%	-6.4%
Aug 29	Cantor Fitzgerald	Maintains	Overweight → Overweight	—	$23.43	$23.37	-0.3%	+1.2%	+0.3%	-1.1%	+0.1%	+1.1%
Aug 9	Barclays	Maintains	Equal Weight → Equal Weight	—	$26.25	$26.41	+0.6%	-0.5%	-3.2%	-2.7%	-3.9%	-7.5%
Aug 9	Credit Suisse	Maintains	Neutral → Neutral	—	$26.25	$26.41	+0.6%	-0.5%	-3.2%	-2.7%	-3.9%	-7.5%
Aug 9	Citigroup	Maintains	Buy → Buy	—	$26.25	$26.41	+0.6%	-0.5%	-3.2%	-2.7%	-3.9%	-7.5%
May 11	RBC Capital	Maintains	Sector Perform → Sector Perform	—	$35.85	$35.58	-0.8%	-1.9%	-7.0%	+0.4%	-5.6%	-2.5%
May 11	Citigroup	Maintains	Buy → Buy	—	$35.85	$35.58	-0.8%	-1.9%	-7.0%	+0.4%	-5.6%	-2.5%
May 11	Barclays	Maintains	Equal Weight → Equal Weight	—	$35.85	$35.58	-0.8%	-1.9%	-7.0%	+0.4%	-5.6%	-2.5%

Recent Filings

8-K · 1.02 !! High

Beam Therapeutics Inc. -- 8-K 1.02: Material Agreement Terminated

Beam Therapeutics terminated a license agreement, which could impact its pipeline development and royalty obligations depending on the licensed technology's strategic importance to the company.

Mar 5

8-K · 1.01 !! High

Beam Therapeutics Inc. -- 8-K 1.01: Material Agreement

Beam Therapeutics secured a $500 million senior secured credit facility with an initial $100 million draw, providing crucial funding for operations and potential future clinical development needs.

Feb 24

8-K · 1.01 !! High

Beam Therapeutics Inc. -- 8-K 1.01: License Agreement

Beam Therapeutics holds sublicensed patent rights from Bio Palette covering Kobe University intellectual property, establishing a tiered licensing structure for the company's therapeutic development.

Feb 12

8-K · 5.02 !!! Very High

Beam Therapeutics Inc. -- 8-K 5.02: Executive Change

Carole Ho's resignation from Beam Therapeutics' board represents a minor leadership transition that investors should monitor for any broader governance changes or strategic shifts.

Feb 5

Data updated apr 24, 2026 9:06pm · Source: massive.com